The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Listing Application and Directors' Dealings

21 Jun 2016 10:47

RNS Number : 8202B
Premier Veterinary Group PLC
21 June 2016
 

 

 

 

EXERCISE OF OPTIONS AND WARRANTS

 

DIRECTOR'S DEALING

 

TOTAL VOTING RIGHTS

 

BLOCK LISTING APPLICATION

 

Exercise of options and warrants

 

London, 21 June 2016: Premier Veterinary Group plc (LSE: PVG) (the "Company") announces that it has received notices of exercise of options under the Company's Enterprise Management Incentive Share Option Plan (the "EMI Plan") from certain employees and a Director of the Company (the "Option Exercise") to subscribe for a total of 816,143 new ordinary shares of 10 pence each in the Company (the "New Ordinary Shares"). The exercise price of the options is 10.1 pence each.

 

In addition, the Company has received notice of exercise of warrants from WG Partners LLP to subscribe for 139,517 New Ordinary Shares at a price of 10.1 pence per share. Warrants over 279,034 ordinary shares of 10 pence each were granted to WG Partners LLP as part of the arrangements relating to the reverse acquisition by the Company of Premier Veterinary Group Limited (now PVG 2007 Limited) completed in February 2015. The balance of the warrants will vest and become exercisable with effect from 27 February 2017.

 

Application has been made to the London Stock Exchange for the admission of a total of 955,660 New Ordinary Shares to the Official List of the UK Listing Authority and to trading on the London Stock Exchange's market for listed securities ("Admission"). Admission is expected to occur on or around 23 June 2016. The New Ordinary Shares will rank pari passu with the existing ordinary shares in the Company.

 

Directors' dealings

 

Included in the above total of 816,143 share options are 209,277 options which were exercised by Daniel Smith, a Director of the Company.

Following the exercise of these options, Daniel Smith owns 209,277 ordinary shares, representing approximately 1.4% of the Company's enlarged issued share capital. Mr Smith holds no further share options.

 

Total voting rights

 

Following Admission, the Company's enlarged issued share capital will comprise 14,907,433 ordinary shares. The Company does not hold any shares in treasury. The figure of 14,907,433 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

 

Block Listing Application

The Company further announces that is has made a block listing application to the London Stock Exchange for the admission of up to 579,035 ordinary shares of 10 pence each to the Official List of the UK Listing Authority and to trading on the London Stock Exchange's market for listed securities.

The block listing application relates to 579,035 shares, being the total number of shares that could be issued pursuant to the exercise of all options currently outstanding under the EMI Plan. If all the options were exercised, the shares that would be issued would represent approximately 3.88% of the enlarged issued share capital.

 

The application for the admission of these shares has been made in advance for ease of administration as all the outstanding options under the EMI Plan vested and became exercisable on 27 February 2016.

Shares issued pursuant to the exercise of options under the EMI Plan will rank pari passu with the existing ordinary shares of 10 pence each in the share capital of the Company.

It is expected that the block admission will become effective on 23 June 2016.

 

 

Enquiries:

 

Premier Veterinary Group plc

Sue Steven, Company Secretary +44 (0)117 370 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGZVLMKGVZG
Date   Source Headline
21st Feb 20117:00 amRNSBoard Change
11th Feb 20117:00 amRNSNotice of Results
8th Feb 20117:00 amRNSDisposal of Majority of Woundcare Business
20th Jan 201112:25 pmRNSHolding(s) in Company
4th Jan 20111:19 pmRNSTotal Voting Rights
16th Dec 20107:00 amRNSChange of Adviser
6th Dec 20109:40 amRNSBlocklisting Interim Review
29th Nov 20101:06 pmRNSHolding(s) in Company
29th Nov 20107:00 amRNSPositive results for pre-clinical product EG013
11th Nov 20107:00 amRNSInterim Management Statement
8th Nov 20102:21 pmRNSHolding(s) in Company
23rd Sep 20104:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20104:35 pmRNSPrice Monitoring Extension
14th Sep 20104:21 pmRNSHolding(s) in Company
14th Sep 20104:19 pmRNSHolding(s) in Company
13th Sep 20103:29 pmRNSDirector/PDMR Shareholding
9th Sep 20107:00 amRNSStrategic Review
31st Aug 201010:33 amRNSTotal Voting Rights
27th Aug 201010:08 amRNSForm 8.5 (EPT/NON-RI)
25th Aug 20107:00 amRNSHalf Yearly Report
20th Aug 20102:27 pmPRNForm 8.3 - Ark Therapeutics Group Plc
19th Aug 201011:35 amRNSForm 8.5 (EPT/NON-RI)
16th Aug 201012:29 pmRNSForm 8.3 - Ark Therapeutics Group plc
16th Aug 20107:00 amRNSForm 8.3 - Ark Therapeutics PLC (Amendment)
13th Aug 20104:24 pmRNSRe EGM
13th Aug 201011:34 amRNSForm 8.5 (EPT/NON-RI)
13th Aug 201011:22 amRNSForm 8.5 (EPT/RI)
13th Aug 201010:30 amRNSForm 8.3 - Ark Therapeutics PLC
11th Aug 201011:35 amRNSForm 8.3 - [Ark Therapeutics Plc]
5th Aug 201012:31 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Aug 20104:41 pmRNSSecond Price Monitoring Extn
4th Aug 20104:35 pmRNSPrice Monitoring Extension
4th Aug 201010:00 amRNSForm 8.3 - Ark Therapeutics Group
3rd Aug 201010:47 amRNSForm 8.3 - Ark Therapeutics
30th Jul 201011:22 amRNSForm 8.3 - Ark Therapeutics Plc
29th Jul 201010:34 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201011:03 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201010:36 amRNSHolding(s) in Company
28th Jul 201010:30 amRNSForm 8.3 - Ark Therapeutics
28th Jul 201010:01 amRNSHolding(s) in Company
26th Jul 20102:57 pmRNSForm 8.3 - [Ark Therapeutics]
26th Jul 20102:41 pmPRNForm 8.3 - ARK THERAPEUTICS
26th Jul 201011:37 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:57 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:15 amRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 20102:34 pmPRNForm 8.3 - Ark Theraputics Plc
22nd Jul 201012:54 pmRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 201011:19 amRNSForm 8.5 (EPT/NON-RI)
22nd Jul 201010:55 amRNSForm 8.3 - Ark Therapeutics Group Plc
21st Jul 20102:41 pmRNSForm 8.3 - Ark Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.